Patients with pulmonary arterial hypertension and iron deficiency in the absence of anemia who received iron supplements did not show significant clinical benefit at 12 weeks.
Patients with pulmonary hypertension and COPD appear to have a poorer prognosis than those with idiopathic pulmonary arterial hypertension.
Since uric acid levels in patients with idiopathic pulmonary arterial hypertension are associated with an impaired clinical and hemodynamic profile, they may serve as a useful noninvasive indicator of disease severity.
In pulmonary arterial hypertension, high plasma levels of hepatic growth factor are associated with the right heart maladaptive phenotype and are incremental to the REVEAL score for the prediction of patient outcomes.
Asymptomatic carriers of the BMPR2 mutation have a significant risk of developing incident pulmonary arterial hypertension.
The new diagnostic criteria for pre-capillary pulmonary hypertension may better recognize patients with early forms of pulmonary vascular disease and poor prognosis.
A collection of algorithms for detecting pulmonary arterial hypertension in administrative data has been developed to enhance the integrity and value of research findings and improve quality of care.
Patients with pulmonary arterial hypertension (PAH) who were treated with treprostinil using an implantable infusion pump experienced few serious complications.
Low-risk status is unattainable for most patients with pulmonary arterial hypertension, and the first year from diagnosis is important in defining the longitudinal risk status.
Physicians frequently underestimate or overestimate disease progression risk in patients with World Health Organization functional class II pulmonary arterial hypertension.
